ArticleEndocrine connections2026
CYP19A1 variation in healthy children: associations with breast development and pubertal gynecomastia.
Article in Endocrine connections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCYP19A1 encodes aromatase, the enzyme converting androgens to estrogens, thereby influencing breast tissue development in healthy children.
objectiveTo examine associations between CYP19A1 single nucleotide polymorphisms (SNPs) and circulating estradiol (E2) and testosterone (T), the E2/T ratio and age at thelarche in girls, and the presence of gynecomastia in boys.
methodsA total of 1,023 healthy participants (aged 5.9-20.0 years) from the Copenhagen Puberty Study were assessed for pubertal status, and serum sex steroid concentrations were measured by LC-MS/MS. Genotyping of CYP19A1 SNPs (rs727479 A>C, rs2899472 A>C and rs10046 C>T) was performed.
resultsGirls with the AA genotype in rs727479 and rs2899472 showed tendencies toward earlier pubertal onset. In a combined efficacy allele model, each additional allele was associated with 1.6 months earlier puberty (P = 0.06), and girls with 5-6 vs 0-2 efficacy alleles presented with significantly lower pubertal age (P = 0.02). The CYP19A1 genotype was not associated with E2, T or E2/T levels. Boys with the CC genotype in rs727479 had the highest prevalence of pubertal gynecomastia (73%, P < 0.01). Boys with gynecomastia showed higher E2 and T (SDS) than unaffected boys (both P < 0.01), with no difference in E2/T. In age-matched analyses, E2 (SDS) remained elevated in boys with gynecomastia (0.81 vs 0.19, P = 0.04).
conclusionCYP19A1 variants may influence pubertal timing in girls. In boys, pubertal gynecomastia appeared to be linked with the CYP19A1 genotype and was associated with elevated E2 concentrations. SIGNIFICANCE STATEMENT: Aromatase, encoded by CYP19A1, catalyzes the conversion of androgens to estrogens. The contribution of common CYP19A1 genetic variants to variation in pubertal development in healthy children is not fully understood. In this cohort from the Copenhagen Puberty Study, we examined associations between CYP19A1 polymorphisms and circulating sex steroid concentrations, age at puberty and pubertal gynecomastia in boys. By integrating genetic, hormonal and clinical pubertal data, this study provides additional insights into potential links between aromatase-related genetic variation and normal pubertal development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.